Home/Filings/4/0001867899-25-000005
4//SEC Filing

Tessari Eben 4

Accession 0001867899-25-000005

CIK 0001730430other

Filed

Sep 30, 8:00 PM ET

Accepted

Oct 1, 4:44 PM ET

Size

9.2 KB

Accession

0001867899-25-000005

Insider Transaction Report

Form 4
Period: 2025-09-29
Tessari Eben
CHIEF OPERATING OFFICER
Transactions
  • Sale

    Class A Ordinary Share

    2025-09-29$38.33/sh42,000$1,609,86034,552 total
  • Exercise/Conversion

    Share Option

    2025-09-2942,0000 total
    Exercise: $17.92Exp: 2029-03-03Class A Ordinary Share (42,000 underlying)
  • Exercise/Conversion

    Class A Ordinary Share

    2025-09-29$17.92/sh+42,000$752,64076,552 total
Footnotes (3)
  • [F1]This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on April 29, 2024.
  • [F2]This transaction was executed in multiple trades through a broker-dealer at prices ranging between $37.92 and $38.85. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.
  • [F3]The option is fully vested and exercisable.

Issuer

Kiniksa Pharmaceuticals International, plc

CIK 0001730430

Entity typeother

Related Parties

1
  • filerCIK 0001867899

Filing Metadata

Form type
4
Filed
Sep 30, 8:00 PM ET
Accepted
Oct 1, 4:44 PM ET
Size
9.2 KB